391 related articles for article (PubMed ID: 36840620)
1. Differences between ante mortem Alzheimer's disease biomarkers in predicting neuropathology at autopsy.
Wang ZB; Tan L; Wang HF; Chen SD; Fu Y; Gao PY; Ma YH; Guo Y; Hou JH; Zhang DD; Yu JT;
Alzheimers Dement; 2023 Aug; 19(8):3613-3624. PubMed ID: 36840620
[TBL] [Abstract][Full Text] [Related]
2. Associations of the A/T/N profiles in PET, CSF, and plasma biomarkers with Alzheimer's disease neuropathology at autopsy.
Wang ZB; Tan L; Gao PY; Ma YH; Fu Y; Sun Y; Yu JT;
Alzheimers Dement; 2023 Oct; 19(10):4421-4435. PubMed ID: 37506291
[TBL] [Abstract][Full Text] [Related]
3. Plasma p-tau181 accurately predicts Alzheimer's disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline.
Lantero Rodriguez J; Karikari TK; Suárez-Calvet M; Troakes C; King A; Emersic A; Aarsland D; Hye A; Zetterberg H; Blennow K; Ashton NJ
Acta Neuropathol; 2020 Sep; 140(3):267-278. PubMed ID: 32720099
[TBL] [Abstract][Full Text] [Related]
4. Correlation between Cerebrospinal Fluid Core Alzheimer's Disease Biomarkers and β-Amyloid PET in Chinese Dementia Population.
Xie Q; Ni M; Gao F; Dai LB; Lv XY; Zhang YF; Shi Q; Zhu XX; Xie JK; Shen Y; Wang SC
ACS Chem Neurosci; 2022 May; 13(10):1558-1565. PubMed ID: 35476397
[TBL] [Abstract][Full Text] [Related]
5. Associating Alzheimer's disease pathology with its cerebrospinal fluid biomarkers.
Bridel C; Somers C; Sieben A; Rozemuller A; Niemantsverdriet E; Struyfs H; Vermeiren Y; Van Broeckhoven C; De Deyn PP; Bjerke M; Nagels G; Teunissen CE; Engelborghs S
Brain; 2022 Nov; 145(11):4056-4064. PubMed ID: 35026840
[TBL] [Abstract][Full Text] [Related]
6. Neuropathological changes associated with aberrant cerebrospinal fluid p-tau181 and Aβ42 in Alzheimer's disease and other neurodegenerative diseases.
Kurihara M; Matsubara T; Morimoto S; Arakawa A; Ohse K; Kanemaru K; Iwata A; Murayama S; Saito Y
Acta Neuropathol Commun; 2024 Mar; 12(1):48. PubMed ID: 38539238
[TBL] [Abstract][Full Text] [Related]
7. The CSF p-tau181/Aβ42 Ratio Offers a Good Accuracy "In Vivo" in the Differential Diagnosis of Alzheimer's Dementia.
Santangelo R; Dell'Edera A; Sala A; Cecchetti G; Masserini F; Caso F; Pinto P; Leocani L; Falautano M; Passerini G; Martinelli V; Comi G; Perani D; Magnani G
Curr Alzheimer Res; 2019; 16(7):587-595. PubMed ID: 31345148
[TBL] [Abstract][Full Text] [Related]
8. Plasma Core Alzheimer's Disease Biomarkers Predict Amyloid Deposition Burden by Positron Emission Tomography in Chinese Individuals with Cognitive Decline.
Ni M; Zhu ZH; Gao F; Dai LB; Lv XY; Wang Q; Zhu XX; Xie JK; Shen Y; Wang SC; Xie Q;
ACS Chem Neurosci; 2023 Jan; 14(1):170-179. PubMed ID: 36547971
[TBL] [Abstract][Full Text] [Related]
9. Robustness of CSF Aβ42/40 and Aβ42/P-tau181 measured using fully automated immunoassays to detect AD-related outcomes.
Leuzy A; Mattsson-Carlgren N; Cullen NC; Stomrud E; Palmqvist S; La Joie R; Iaccarino L; Zetterberg H; Rabinovici G; Blennow K; Janelidze S; Hansson O
Alzheimers Dement; 2023 Jul; 19(7):2994-3004. PubMed ID: 36681387
[TBL] [Abstract][Full Text] [Related]
10. The dynamics of plasma biomarkers across the Alzheimer's continuum.
Guo Y; Shen XN; Wang HF; Chen SD; Zhang YR; Chen SF; Cui M; Cheng W; Dong Q; Ma T; Yu JT
Alzheimers Res Ther; 2023 Feb; 15(1):31. PubMed ID: 36750875
[TBL] [Abstract][Full Text] [Related]
11. Exploring the potential of fully automated LUMIPULSE G plasma assays for detecting Alzheimer's disease pathology.
Silva-Spínola A; Leitão MJ; Nadal A; Le Bastard N; Santana I; Baldeiras I
Alzheimers Res Ther; 2024 Mar; 16(1):51. PubMed ID: 38454502
[TBL] [Abstract][Full Text] [Related]
12. The Bio-Hermes Study: Biomarker database developed to investigate blood-based and digital biomarkers in community-based, diverse populations clinically screened for Alzheimer's disease.
Mohs RC; Beauregard D; Dwyer J; Gaudioso J; Bork J; MaGee-Rodgers T; Key MN; Kerwin DR; Hughes L; Cordell CB;
Alzheimers Dement; 2024 Apr; 20(4):2752-2765. PubMed ID: 38415908
[TBL] [Abstract][Full Text] [Related]
13. Ante-mortem plasma phosphorylated tau (181) predicts Alzheimer's disease neuropathology and regional tau at autopsy.
Morrison MS; Aparicio HJ; Blennow K; Zetterberg H; Ashton NJ; Karikari TK; Tripodis Y; Martin B; Palmisano JN; Sugarman MA; Frank B; Steinberg EG; Turk KW; Budson AE; Au R; Goldstein LE; Jun GR; Kowall NW; Killiany R; Qiu WQ; Stern RA; Mez J; McKee AC; Stein TD; Alosco ML
Brain; 2022 Oct; 145(10):3546-3557. PubMed ID: 35554506
[TBL] [Abstract][Full Text] [Related]
14. Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology.
Ashton NJ; Pascoal TA; Karikari TK; Benedet AL; Lantero-Rodriguez J; Brinkmalm G; Snellman A; Schöll M; Troakes C; Hye A; Gauthier S; Vanmechelen E; Zetterberg H; Rosa-Neto P; Blennow K
Acta Neuropathol; 2021 May; 141(5):709-724. PubMed ID: 33585983
[TBL] [Abstract][Full Text] [Related]
15. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Plasma Biomarkers for A/T/N Classification of Alzheimer Disease Among Adults of Caribbean Hispanic Ethnicity.
Honig LS; Kang MS; Lee AJ; Reyes-Dumeyer D; Piriz A; Soriano B; Franco Y; Coronado ZD; Recio P; Mejía DR; Medrano M; Lantigua RA; Teich AF; Dage JL; Mayeux R
JAMA Netw Open; 2023 Apr; 6(4):e238214. PubMed ID: 37079306
[TBL] [Abstract][Full Text] [Related]
17. Alzheimer's cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans : CSF AD biomarkers measured by Lumipulse in Koreans.
Moon S; Kim S; Mankhong S; Choi SH; Vandijck M; Kostanjevecki V; Jeong JH; Yoon SJ; Park KW; Kim EJ; Yoon B; Kim HJ; Jang JW; Hong JY; Park DH; Shaw LM; Kang JH
Alzheimers Res Ther; 2021 Jan; 13(1):22. PubMed ID: 33436035
[TBL] [Abstract][Full Text] [Related]
18. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
[TBL] [Abstract][Full Text] [Related]
19. Preclinical Alzheimer's disease biomarkers accurately predict cognitive and neuropathological outcomes.
Long JM; Coble DW; Xiong C; Schindler SE; Perrin RJ; Gordon BA; Benzinger TLS; Grant E; Fagan AM; Harari O; Cruchaga C; Holtzman DM; Morris JC
Brain; 2022 Dec; 145(12):4506-4518. PubMed ID: 35867858
[TBL] [Abstract][Full Text] [Related]
20. Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer's Disease Pathology Between Three Independent Assay Platforms.
Doecke JD; Rembach A; Villemagne VL; Varghese S; Rainey-Smith S; Sarros S; Evered LA; Fowler CJ; Pertile KK; Rumble RL; Trounson B; Taddei K; Laws SM; Macaulay SL; Bush AI; Ellis KA; Martins R; Ames D; Silbert B; Vanderstichele H; Masters CL; Darby DG; Li QX; Collins S;
J Alzheimers Dis; 2018; 61(1):169-183. PubMed ID: 29171991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
